Diagnostic Ultrasound - Abdomen and Pelvis
Mucinous Ovarian Cystadenoma/Carcinoma TERMINOLOGY Abbreviations • Benign or malignant mucinous tumor Definitions • Mucinous epithelial neoplasm, which can be benign (mucinous cystadenoma), borderline (low malignant potential), or malignant (mucinous cystadenocarcinoma) IMAGING General Features • Best diagnostic clue ○ Multilocular cystic mass with low-level internal echoes • Location ○ Bilateral in 5% of benign and 20% of malignant tumors • Size ○ Variable in size, but often large, filling entire pelvis and extending into upper abdomen ○ Some of the largest tumors ever reported are mucinous cystadenomas – Massive size alone can suggest mucinous etiology Ultrasonographic Findings • Grayscale ultrasound ○ Typically multiloculated with thin septations ○ Papillary projections much less common than in serous tumors ○ Mucin creates low-level echoes within loculi – Typically have multiple loculi of varying echogenicity – Echogenicity variable depending on concentration of mucin ○ Solid components increase suspicion for malignancy ○ Pseudomyxoma peritonei: Potential form of peritoneal spread with amorphous, mucoid material insinuating itself around mesentery, bowel, and solid organs – More echogenic than simple ascites – Has mass effect with scalloping along solid organs (especially liver) and bowel matted posteriorly (rather than free floating) – May have subtle septations • Color Doppler ○ Vascularity seen within solid components CT Findings • Variable attenuation of loculi, depending on concentration of mucin • Peritoneal metastases often low attenuation ○ May be difficult to differentiate from fluid-filled bowel • Enhancement of solid portions with contrast MR Findings • Signal intensity varies depending on concentration of mucin • Loculi with high concentration of mucin will be higher signal on T1WI and lower signal on T2WI ○ Creates a stained glass appearance DIFFERENTIAL DIAGNOSIS Endometriomas • Also contain low-level echoes • MRI helpful: Blood high signal on T1WI with T2 shading Serous Cystadenoma/Carcinoma • More often unilocular • Cyst contents not as echogenic • Papillary projections common Germ Cell Tumors • Can have low-level echoes similar to mucin • Typically more complicated with calcifications, fluid-fluid levels, etc. Hemorrhagic Cyst • Smaller and unilocular • Resolves on follow-up scan Mucocele • Dilated appendix filled with mucinous material PATHOLOGY General Features • Etiology ○ Not completely understood ○ 1 theory is "incessant ovulation": Repeated microtrauma with cellular repair to surface epithelium – Increased risk: Nulliparity, early menarche, late menopause (more ovulatory cycles) – Reduced risk: Multiparity, late menarche, early menopause, oral contraceptive use (fewer ovulatory cycles) • Genetics ○ Hereditary causes in 5-10% of ovarian cancers (mutations in BRCA1 and BRCA2 tumor suppressor genes) • Associated abnormalities ○ May occasionally be hormonally active, producing estrogen • Ovarian neoplasms ○ Epithelial tumors: 60-70% of all tumors; 85-90% of malignancies ○ Germ cell tumors: 15-20% of all tumors; 3-5% of malignancies ○ Sex cord-stromal tumors: 5-10% of all tumors; 2-3% of malignancies ○ Metastases and lymphoma: 5-10% of all tumors; 5-10% of malignancies • Benign epithelial tumors ○ Serous cystadenoma: 20-25% ○ Mucinous cystadenoma: 20-25% • Malignant epithelial tumors ○ Serous cystadenocarcinoma: 40-50% ○ Endometrioid carcinoma: 20-25% ○ Mucinous cystadenocarcinoma: 5-10% ○ Clear cell carcinoma: 5-10% ○ Brenner tumor: 1-2% ○ Undifferentiated carcinoma: 4-5% • Method of spread ○ Intraperitoneal dissemination most common – Greater omentum, right subphrenic region, and pouch of Douglas most common sites found at surgery ○ Direct extension to surrounding organs ○ Lymphatic spread to paraaortic and pelvic nodes ○ Hematogenous spread least common Diagnoses: Female Pelvis 817
Mucinous Ovarian Cystadenoma/Carcinoma Diagnoses: Female Pelvis – Liver and lung most common sites Staging, Grading, & Classification • FIGO staging system of ovarian carcinoma ○ Stage I: Tumor limited to ovaries – IA: Unilateral, no malignant ascites – IB: Bilateral, no malignant ascites – IC: Tumor limited to 1 or both ovaries with any of the following □ IC1: Surgical spill intraoperatively □ IC2: Capsule rupture before surgery, or tumor on ovarian/fallopian tube surface □ IC3: Malignant cells present in ascites or peritoneal washings ○ Stage II: Tumor involves 1 or both ovaries with pelvic extension – IIA: Extension to uterus or fallopian tubes, no malignant ascites – IIB: Extension to other pelvic tissues, no malignant ascites ○ Stage III: Peritoneal implants outside pelvis &/or retroperitoneal nodal metastases – IIIA1: Positive retroperitoneal lymph nodes only – IIIA2: Microscopic metastasis outside pelvis &/or positive retroperitoneal lymph nodes – IIIB: Macroscopic extrapelvic implants ≤ 2 cm ± positive nodes – IIIC: Macroscopic extrapelvic implants > 2 cm or ± positive nodes ○ Stage IV: Distant metastases (excluding peritoneal implants) – IVA: Pleural effusion with positive cytology – IVB: Hepatic &/or splenic parenchymal metastasis, or metastasis to extra-abdominal organs (including inguinal nodes and nodes outside of abdomen) Microscopic Features • Ovarian origin of pseudomyxoma peritonei called into question ○ Most cases now thought to be appendiceal with metastases to ovary ○ Appendix should be thoroughly examined with special tissue staining in every case CLINICAL ISSUES Presentation • Most common signs/symptoms ○ Incidental mass discovered on exam ○ Pelvic discomfort/pain from large tumors – Massive tumors can actually cause weight gain and distended abdomen ○ Symptoms from metastatic disease • CA-125 not useful for mucinous tumors: False-negative in 30% Demographics • Age ○ Mucinous cystadenoma 3rd-5th decade ○ Mucinous cystadenocarcinoma in peri- and postmenopausal age group • Epidemiology ○ Mucinous tumors 2nd most common epithelial neoplasm (serous most common) ○ Malignant: 10%; borderline: (Low malignant potential) 10%; benign 80% ○ Bilateral in 5% of benign tumors, 10% of borderline tumors and 20% of malignant tumors Natural History & Prognosis • 95% 5-year survival for low malignant potential tumors ○ If metastatic, prognosis is similar to those with frankly malignant histology • 5-year survival for malignant epithelial tumors ○ Stage I: 90% ○ Stage II: 70% ○ Stage III: 39% ○ Stage IV: 17% Treatment • Primary treatment is surgery ○ Complete staging laparotomy and tumor debulking (cytoreduction) – Staging laparotomy includes hysterectomy with bilateral salpingo-oophorectomy, pelvic and paraaortic node biopsies, omentectomy, peritoneal biopsies and washings – More conservative surgery may be done for women with stage I disease in reproductive age group – Care taken to avoid intraoperative rupture □ May increase potential for recurrence ○ Gelatinous, insinuating nature of pseudomyxoma peritonei makes complete resection difficult – Recurrence common and multiple laparotomies required ○ Chemotherapy after cytoreductive surgery ○ Neoadjuvant chemotherapy before cytoreductive surgery in patients with unresectable disease – Includes bulky disease in difficult to reach areas (porta hepatis, lesser sac, root of mesentery), extensive surrounding organ or sidewall invasion, or stage IV disease DIAGNOSTIC CHECKLIST Image Interpretation Pearls • Mucinous tumors are less commonly malignant than serous tumors SELECTED REFERENCES 1. Sayasneh A et al: The characteristic ultrasound features of specific types of ovarian pathology (Review). Int J Oncol. 46(2):445-58, 2015 2. Ledermann JA et al: Gynecologic Cancer InterGroup (GCIG) consensus review for mucinous ovarian carcinoma. Int J Gynecol Cancer. 24(9 Suppl 3):S14-9, 2014 3. Alcázar JL et al: Clinical and ultrasound features of type I and type II epithelial ovarian cancer. Int J Gynecol Cancer. 23(4):680-4, 2013 4. Lalwani N et al: Histologic, molecular, and cytogenetic features of ovarian cancers: implications for diagnosis and treatment. Radiographics. 31(3):625- 46, 2011 818
- Page 788 and 789: Endometritis TERMINOLOGY Synonyms
- Page 790 and 791: Endometritis (Left) Longitudinal tr
- Page 792 and 793: Intrauterine Device TERMINOLOGY Abb
- Page 794 and 795: Intrauterine Device (Left) Longitud
- Page 796 and 797: Tubal Ectopic Pregnancy TERMINOLOGY
- Page 798 and 799: Tubal Ectopic Pregnancy (Left) Tran
- Page 800 and 801: Tubal Ectopic Pregnancy (Left) Sagi
- Page 802 and 803: Unusual Ectopic Pregnancies TERMINO
- Page 804 and 805: Unusual Ectopic Pregnancies (Left)
- Page 806 and 807: Unusual Ectopic Pregnancies (Left)
- Page 808 and 809: Failed First Trimester Pregnancy TE
- Page 810 and 811: Failed First Trimester Pregnancy (L
- Page 812 and 813: Failed First Trimester Pregnancy (L
- Page 814 and 815: Retained Products of Conception TER
- Page 816 and 817: Retained Products of Conception (Le
- Page 818 and 819: Gestational Trophoblastic Disease T
- Page 820 and 821: Gestational Trophoblastic Disease (
- Page 822 and 823: Functional Ovarian Cyst TERMINOLOGY
- Page 824 and 825: Functional Ovarian Cyst (Left) Typi
- Page 826 and 827: Hemorrhagic Cyst TERMINOLOGY Abbrev
- Page 828 and 829: Hemorrhagic Cyst (Left) Using color
- Page 830 and 831: Ovarian Hyperstimulation Syndrome T
- Page 832 and 833: Ovarian Hyperstimulation Syndrome (
- Page 834 and 835: Serous Ovarian Cystadenoma/Carcinom
- Page 836 and 837: Serous Ovarian Cystadenoma/Carcinom
- Page 840 and 841: Mucinous Ovarian Cystadenoma/Carcin
- Page 842 and 843: Ovarian Teratoma TERMINOLOGY Synony
- Page 844 and 845: Ovarian Teratoma (Left) Ultrasound
- Page 846 and 847: Polycystic Ovarian Syndrome TERMINO
- Page 848 and 849: Endometrioma TERMINOLOGY Synonyms
- Page 850 and 851: Endometrioma (Left) Longitudinal en
- Page 852 and 853: Hydrosalpinx TERMINOLOGY Definition
- Page 854 and 855: Hydrosalpinx (Left) Longitudinal tr
- Page 856 and 857: Tubo-Ovarian Abscess TERMINOLOGY De
- Page 858 and 859: Tubo-Ovarian Abscess (Left) Longitu
- Page 860 and 861: Parovarian Cyst TERMINOLOGY Abbrevi
- Page 862 and 863: Peritoneal Inclusion Cyst TERMINOLO
- Page 864 and 865: Peritoneal Inclusion Cyst (Left) Sa
- Page 866 and 867: Bartholin Cyst TERMINOLOGY Definiti
- Page 868 and 869: Gartner Duct Cyst TERMINOLOGY Abbre
- Page 870 and 871: Gartner Duct Cyst (Left) Longitudin
- Page 872 and 873: Sex Cord-Stromal Tumor TERMINOLOGY
- Page 874 and 875: Sex Cord-Stromal Tumor (Left) Trans
- Page 876 and 877: Sex Cord-Stromal Tumor (Left) Sagit
- Page 878 and 879: Adnexal/Ovarian Torsion TERMINOLOGY
- Page 880 and 881: Adnexal/Ovarian Torsion (Left) Long
- Page 882 and 883: Ovarian Metastases Including Kruken
- Page 884 and 885: Ovarian Metastases Including Kruken
- Page 886 and 887: PART III SECTION 1 Liver Hepatomega
Mucinous Ovarian Cystadenoma/Carcinoma<br />
TERMINOLOGY<br />
Abbreviations<br />
• Benign or malignant mucinous tumor<br />
Definitions<br />
• Mucinous epithelial neoplasm, which can be benign<br />
(mucinous cystadenoma), borderline (low malignant<br />
potential), or malignant (mucinous cystadenocarcinoma)<br />
IMAGING<br />
General Features<br />
• Best diagnostic clue<br />
○ Multilocular cystic mass with low-level internal echoes<br />
• Location<br />
○ Bilateral in 5% of benign <strong>and</strong> 20% of malignant tumors<br />
• Size<br />
○ Variable in size, but often large, filling entire pelvis <strong>and</strong><br />
extending into upper abdomen<br />
○ Some of the largest tumors ever reported are mucinous<br />
cystadenomas<br />
– Massive size alone can suggest mucinous etiology<br />
Ultrasonographic Findings<br />
• Grayscale ultrasound<br />
○ Typically multiloculated with thin septations<br />
○ Papillary projections much less common than in serous<br />
tumors<br />
○ Mucin creates low-level echoes within loculi<br />
– Typically have multiple loculi of varying echogenicity<br />
– Echogenicity variable depending on concentration of<br />
mucin<br />
○ Solid components increase suspicion for malignancy<br />
○ Pseudomyxoma peritonei: Potential form of peritoneal<br />
spread with amorphous, mucoid material insinuating<br />
itself around mesentery, bowel, <strong>and</strong> solid organs<br />
– More echogenic than simple ascites<br />
– Has mass effect with scalloping along solid organs<br />
(especially liver) <strong>and</strong> bowel matted posteriorly (rather<br />
than free floating)<br />
– May have subtle septations<br />
• Color Doppler<br />
○ Vascularity seen within solid components<br />
CT Findings<br />
• Variable attenuation of loculi, depending on concentration<br />
of mucin<br />
• Peritoneal metastases often low attenuation<br />
○ May be difficult to differentiate from fluid-filled bowel<br />
• Enhancement of solid portions with contrast<br />
MR Findings<br />
• Signal intensity varies depending on concentration of mucin<br />
• Loculi with high concentration of mucin will be higher signal<br />
on T1WI <strong>and</strong> lower signal on T2WI<br />
○ Creates a stained glass appearance<br />
DIFFERENTIAL DIAGNOSIS<br />
Endometriomas<br />
• Also contain low-level echoes<br />
• MRI helpful: Blood high signal on T1WI with T2 shading<br />
Serous Cystadenoma/Carcinoma<br />
• More often unilocular<br />
• Cyst contents not as echogenic<br />
• Papillary projections common<br />
Germ Cell Tumors<br />
• Can have low-level echoes similar to mucin<br />
• Typically more complicated with calcifications, fluid-fluid<br />
levels, etc.<br />
Hemorrhagic Cyst<br />
• Smaller <strong>and</strong> unilocular<br />
• Resolves on follow-up scan<br />
Mucocele<br />
• Dilated appendix filled with mucinous material<br />
PATHOLOGY<br />
General Features<br />
• Etiology<br />
○ Not completely understood<br />
○ 1 theory is "incessant ovulation": Repeated microtrauma<br />
with cellular repair to surface epithelium<br />
– Increased risk: Nulliparity, early menarche, late<br />
menopause (more ovulatory cycles)<br />
– Reduced risk: Multiparity, late menarche, early<br />
menopause, oral contraceptive use (fewer ovulatory<br />
cycles)<br />
• Genetics<br />
○ Hereditary causes in 5-10% of ovarian cancers (mutations<br />
in BRCA1 <strong>and</strong> BRCA2 tumor suppressor genes)<br />
• Associated abnormalities<br />
○ May occasionally be hormonally active, producing<br />
estrogen<br />
• Ovarian neoplasms<br />
○ Epithelial tumors: 60-70% of all tumors; 85-90% of<br />
malignancies<br />
○ Germ cell tumors: 15-20% of all tumors; 3-5% of<br />
malignancies<br />
○ Sex cord-stromal tumors: 5-10% of all tumors; 2-3% of<br />
malignancies<br />
○ Metastases <strong>and</strong> lymphoma: 5-10% of all tumors; 5-10%<br />
of malignancies<br />
• Benign epithelial tumors<br />
○ Serous cystadenoma: 20-25%<br />
○ Mucinous cystadenoma: 20-25%<br />
• Malignant epithelial tumors<br />
○ Serous cystadenocarcinoma: 40-50%<br />
○ Endometrioid carcinoma: 20-25%<br />
○ Mucinous cystadenocarcinoma: 5-10%<br />
○ Clear cell carcinoma: 5-10%<br />
○ Brenner tumor: 1-2%<br />
○ Undifferentiated carcinoma: 4-5%<br />
• Method of spread<br />
○ Intraperitoneal dissemination most common<br />
– Greater omentum, right subphrenic region, <strong>and</strong> pouch<br />
of Douglas most common sites found at surgery<br />
○ Direct extension to surrounding organs<br />
○ Lymphatic spread to paraaortic <strong>and</strong> pelvic nodes<br />
○ Hematogenous spread least common<br />
Diagnoses: Female <strong>Pelvis</strong><br />
817